The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study | Zendy

Stuart J. Connolly | Zendy; Lars Wallentin | Zendy; Michael D. Ezekowitz | Zendy; John W. Eikelboom | Zendy; Jonas Oldgren | Zendy; Paul Reilly | Zendy; Martina Brueckmann | Zendy; Janice Pogue | Zendy; Marco Alings | Zendy; John Amerena | Zendy; Álvaro Avezum | Zendy; Iris Baumgärtner | Zendy; Andrzej Budaj | Zendy; Jyh-Hong Chen | Zendy; Antonio L. Dans | Zendy; Harald Darius | Zendy; Giuseppe Di Pasquale | Zendy; Jorge Ferreira | Zendy; Greg C. Flaker | Zendy; Marcus Flather | Zendy; Maria Grazia Franzosi | Zendy; Golitsyn Sp | Zendy; David A. Halon | Zendy; Hein Heidbüchel | Zendy; Stefan H. Hohnloser | Zendy; Kurt Huber | Zendy; Petr Janský | Zendy; Gabriel Kamenský | Zendy; Matyàs Keltai | Zendy; Sung Soon Kim | Zendy; ChuPak Lau | Zendy; Jean-Yves Le Heuzey | Zendy; Basil S. Lewis | Zendy; Lisheng Liu | Zendy; John N. Nanas | Zendy; Razali Omar | Zendy; Prem Pais | Zendy; Knud Erik Pedersen | Zendy; Leopoldo Soares Piegas | Zendy; Dimitar Raev | Zendy; Pål J. Smith | Zendy; Mario Talajic | Zendy; Ru San Tan | Zendy; Supachai Tanomsup | Zendy; Lauri Toivonen | Zendy; Dragoş Vinereanu | Zendy; Denis Xavier | Zendy; Jun Zhu | Zendy; Susan Q. Wang | Zendy; Christine Duffy | Zendy; Ellison Themeles | Zendy; Salim Yusuf | Zendy

Open Access

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

Author(s) -

Stuart J. Connolly,

Lars Wallentin,

Michael D. Ezekowitz,

John W. Eikelboom,

Jonas Oldgren,

Paul Reilly,

Martina Brueckmann,

Janice Pogue,

Marco Alings,

John Amerena,

Álvaro Avezum,

Iris Baumgärtner,

Andrzej Budaj,

Jyh-Hong Chen,

Antonio L. Dans,

Harald Darius,

Giuseppe Di Pasquale,

Jorge Ferreira,

Greg C. Flaker,

Marcus Flather,

Maria Grazia Franzosi,

Golitsyn Sp,

David A. Halon,

Hein Heidbüchel,

Stefan H. Hohnloser,

Kurt Huber,

Petr Janský,

Gabriel Kamenský,

Matyàs Keltai,

Sung Soon Kim,

ChuPak Lau,

Jean-Yves Le Heuzey,

Basil S. Lewis,

Lisheng Liu,

John N. Nanas,

Razali Omar,

Prem Pais,

Knud Erik Pedersen,

Leopoldo Soares Piegas,

Dimitar Raev,

Pål J. Smith,

Mario Talajic,

Ru San Tan,

Supachai Tanomsup,

Lauri Toivonen,

Dragoş Vinereanu,

Denis Xavier,

Jun Zhu,

Susan Q. Wang,

Christine Duffy,

Ellison Themeles,

Salim Yusuf

Publication year - 2013

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.001139

Subject(s) - medicine , dabigatran , hazard ratio , atrial fibrillation , confidence interval , stroke (engine) , cardiology , warfarin , mechanical engineering , engineering

During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research